Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Oxford BioMedica provides update on TroVax development

Oct. 11, 2012

Genentech begins phase II trials of ADCs based on Seattle Genetics technology

Oct. 11, 2012

MedImmune enters immunotherapy collaboration with cancer organizations

Oct. 10, 2012

Dendritic cell vaccine compared to tumor cell vaccine in patients with metastatic melanoma

Oct. 10, 2012

Dendritic cell vaccines improve survival rate in melanoma

Oct. 10, 2012

Preclinical profile of the prostate cancer vaccine candidate AEZS-120

Oct. 8, 2012

OncoMed Pharmaceuticals advances two Notch pathway product candidates

Oct. 5, 2012

HyperAcute Lung advances to phase IIb/III trial

Oct. 5, 2012

Therapy targeting tumor antigens and immune tolerance evaluated in phase I study

Oct. 5, 2012

Progenics Pharmaceuticals begins phase II PSMA-ADC trial in prostate cancer

Oct. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...